Home » Blog » AHCA Pulled, End of Life Models, Biosimilars, MACRA, ASCO Lifting COI Restrictions

AHCA Pulled, End of Life Models, Biosimilars, MACRA, ASCO Lifting COI Restrictions


IP Blog | Dave Melin | March 26, 2017

BioBlog Weekly oncologyIn this week’s BioBlog we look at the American Health Care Act being pulled, new research in various end of life models, the use of biosimilars to lower the cost of drug therapy, MACRA implementation, and ASCO removing conflict of interest restrictions on researchers.

House Republicans Pull Health Care Bill

Since they didn’t have the votes to pass it, Republicans pull the AHCA bill before voting on it, .

Oncology Medical Homes, Patient Navigators Improved Quality and Saved Costs at End of Life 

This article looks at the results of studies done with three different end of life models in an effort to reduce costs and increase quality of life.

Biosimilars In Oncology: Reality Could Bite the Copycats, Dog Potential Major Savings

In the future biosimilars may pave the way for lower-cost drug therapy, making it more accessible for patients.

MACRA Implementation Has Begun: Will You Avoid a 4 Percent Reimbursement Penalty?

Starting January 2017 MACRA went into place, but 2017 is a transition year and practices can begin implementing at their own pace. Read the article for further details and tips to help.

ASCO Removes Restrictions on Researchers’ Conflict of Interest

Recently ASCO removed these restrictions, which only made up a small percentage of the journals and abstracts.


Topics in this Post:



Leave a Comment

Your email address will not be published. Required fields are marked *